Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients

Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients

The emerging debate between primary tumor location and clinical outcome of bevacizumab treated metastatic colorectal cancer (mCRC) continues. The aim of the present study is to investigate the association between the primary tumor location and clinical outcome of 115 mCRC patients receiving bevacizu...

Full description

Bibliographic Details
Main Authors: Xia-Hong You, Can Wen, Zi-Jin Xia, Fan Sun, Yao Li, Wei Wang, Zhou Fang, Qing-Gen Chen, Lei Zhang, Yu-Huang Jiang, Xiao-Zhong Wang, Hou-Qun Ying, Zhen Zong
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-08-01
Series:Frontiers in Oncology
Subjects:
primary tumor sidedness
bevacizumab
mCRC
prognosis
survival
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00723/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00723/full

Similar Items